Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of subcutaneous TQB2922 plus chemotherapy as first-line treatment for RAS/BRAF wild-type unresectable metastatic colorectal cancer
CTR20263729Phase 2Active
- Sponsor
- China Grand Pharmaceutical and Healthcare Holdings
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tqb2922 in colorectal cancer (CRC), sponsored by China Grand Pharmaceutical and Healthcare Holdings. Started Sep 2026; status: active.
02
Drugs
tqb2922
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20263729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263729.